In future studies it may be valuable to test this treatment approach in combination with inhibitors targeting these additional checkpoint ligands to further enhance the magnitude and/or duration of anti-tumor immunity stimulated by BEMPEG and anti-CTLA-4. The gene discussed is CTLA4; the disease is neoplasm.